Results 81 to 90 of about 35,072 (188)

Defining medication adherence in individual patients

Patient Preference and Adherence, 2015
Alan Morrison, Melissa E Stauffer, Anna S Kaufman ScribCo, Effort, PA, USA Background: The classification of patients as adherent or non-adherent to medications is typically based on an arbitrary threshold for the proportion of prescribed doses taken ...
Morrison A, Stauffer ME, Kaufman AS
doaj  

Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register study

Journal of Dermatological Treatment
Background The advent of biosimilars may increase the frequency of dose escalation with biologics in psoriasis.Objective To explore the frequency and outcomes of dose escalation with adalimumab etanercept, and ustekinumab.Methods Data were extracted from
Axel Svedbom, Christina Wennerström, Fredrik Hjelm, Anna Tjärnlund, Mona Ståhle   +4 more
doaj   +1 more source

Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease

RMD Open
Objectives Evaluate the risks and benefits of upadacitinib 15 mg vs adalimumab in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate based on cardiovascular (CV) risk.Methods In SELECT-COMPARE, patients received upadacitinib ...
Roy Fleischmann, Stephen Hall, Gerd R Burmester, Eduardo Mysler, Peter Taylor, Tianming Gao, Sander Strengholt, Bettina Wick-Urban, Andrew Garrison, Irina Fish   +9 more
doaj   +1 more source

Management of Crohn's disease in poor responders to adalimumab

Clinical and Experimental Gastroenterology, 2014
Nanne KH de Boer,1 Mark Löwenberg,2 Frank Hoentjen3 1Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, the Netherlands; 2Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the ...
de Boer NKH, Löwenberg M, Hoentjen F   +2 more
doaj  

Therapeutic drug monitoring and immunogenetic factors associated with the use of adalimumab in Crohn’s disease patients

International Journal of Immunopathology and Pharmacology
Crohn’s disease (CD) involves immune system interactions with intestinal tissue, driven by pro-inflammatory cytokines like Tumor Necrosis Factor (TNF-α). Adalimumab, targeting TNF-α, regulates associated inflammatory responses.
Livia Moreira Genaro, Juliana Carron, Marina Moreira de Castro, Ana Paula Menezes de Freitas Franceschini, Gustavo Jacob Lourenço, Cristiane Kibune Nagasako Vieira da Cruz, Glaucia Fernanda Soares Rupert Reis, Livia Bitencourt Pascoal, Juliana Delgado Campos Mello, Isabela Machado Pereira, Millene Leal Nascimento, Priscilla De Sene Portel Oliveira, Ligiana Pires Corona, Maria de Lourdes Setsuko Ayrizono, Carmen Silvia Passos Lima, Raquel Franco Leal   +15 more
doaj   +1 more source

Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature

Biologics: Targets & Therapy, 2009
Jochen Schmitt, Gottfried WozelDepartment of Dermatology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, GermanyAbstract: Psoriasis is a chronic inflammatory disease affecting 2% to 3% of the population in Western countries ...
Jochen Schmitt, Gottfried Wozel
doaj  

Paradoxical SAPHO syndrome observed during anti-TNF-α therapy for Crohn's disease

Biologics: Targets & Therapy, 2017
Hitoshi Amano,1 Reikei Matsuda,1 Tomohiko Shibata,2 Daisuke Takahashi,1 Shinichiro Suzuki3 1Department of Gastroenterology, Fujisawa Shonandai Hospital, Fujisawa, 2Division of Rheumatology, Department of Internal Medicine, St Marianna University School ...
Amano H, Matsuda R, Shibata T, Takahashi D, Suzuki S   +4 more
doaj  

Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study. [PDF]

RMD Open
Fleischmann R, Swierkot J, Durez P, Bessette L, Blanco R, Van den Bosch F, Geem D, Luo L, Smith LD, Caballero D, Meerwein S, Peterfy C, Tanaka Y, Mysler E.   +13 more
europepmc   +1 more source

Detection of Anti-Infliximab and Anti-Adalimumab Antibodies Below Manufacture's Threshold in a TDM Cohort Using Signal-to-Noise Ratio. [PDF]

Basic Clin Pharmacol Toxicol
Pedersen L.
europepmc   +1 more source

Adalimumab Reprograms M1 Macrophages to Attenuate Th1/Th17 Responses in Behçet's Uveitis and Vogt-Koyanagi-Harada Syndrome. [PDF]

Invest Ophthalmol Vis Sci
Zhu Y, Yu Q, Ma Y, Huang L, Ding J, Gao X, Ma L, Zhang D, Zhang B, Wang S, Chu WK, Su G, Yang P.   +12 more
europepmc   +1 more source